NL-OMON47771已完成2 期
An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone. - Denosumab in patients with giant cell rich tumors of bone.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •The population will consist of patients with the following tumor types:;- Pathologically proven giant cell rich tumor ;* ABC;* GCG;* Other giant cell rich lesions (primary bone, non-malignant, pathology and radiology to be reviewed during multidisciplinary meeting LUMC);- Patients with surgically unsalvageable disease (e.g., sacral, spinal giant cell rich tumors, or multiple lesions including pulmonary metastases) OR patients whose planned surgery includes joint resection, limb amputation, hemipelvectomy or surgical procedure resulting in severe morbidity;- Measurable evidence of active disease within 1 year before study enrollment;- Albumin-adjusted serum calcium level * 2.0 mmol/L (8.0 mg/dL);- Aged 18 years and up and skeletally mature ;- ECOG performance status 0, 1 or 2;- Written signed informed consent
排除标准
- •- Known or suspected current diagnosis of classic GCTB;- Known or suspected current diagnosis of underlying malignancy including but not limited to high-grade sarcoma, osteosarcoma, fibrosarcoma, malignant giant cell sarcoma;- Known or suspected current diagnosis of brown cell tumor of hyperparathyroidism, Paget*s disease or cherubism;- Known or suspected current diagnosis of primary soft tissue tumor with invasion of the bone ;- Known diagnosis of other malignancy within the past 5 years (patients with definitively treated basal cell carcinoma and cervical carcinoma in situ are permitted);- Previous treatment with denosumab (with the exception of patients eligible for re-treatment with denosumab after completing this study);- Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw;- Active dental or jaw condition which requires oral surgery, including tooth extraction;- Non-healed dental/oral surgery;- Planned invasive dental procedure for the course of the study;- Known hypersensitivity to denosumab;- Known hypersensitivity to products to be administered during the study (calcium and/or vitamin D) ;- Currently receiving other specific treatment for giant cell rich tumors of bone (e.g., radiation, chemotherapy or embolization);- Concurrent bisphosphonate treatment;- Major surgery less than 4 weeks prior to start of treatment;- Treatment with other investigational device or drug 30 days prior to study enrollment ;- Unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months before study enrollment;- Patient is pregnant or breast feeding, or planning to become pregnant within 5 months after the EOT visit;- Patient or partner of patient of child bearing potential is not willing to use a highly effective method of contraception during treatment and for 5 months after the EOT visit;- Patient has any kind of disorder that compromises the ability of the patient to give written informed consent and/or to comply with study procedures
研究者
相似试验
已完成
2 期
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitisinflamatory bowel disease10017969Ulcerative colitisNL-OMON46940Eli Lilly and Company7
已完成
2 期
A Phase 2b Multicentre, Randomised, Double-Blind, Active Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2Chronic Kidney DiseaseNL-OMON52170Astra Zeneca9
已完成
2 期
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS)Motor Neuron DiseaseAmyotrophic Lateral Sclerosism (ALS)10029317NL-OMON45879Cytokinetics, Inc.11
已完成
2 期
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Heterozygous Familial HypercholesterolemiaHeterozygous Familial HypercholesterolemiaNL-OMON45499Madrigal Pharmaceuticals, Inc.24
已完成
2 期
A phase IIa, placebo-controlled, double blind, randomised multicentre pilot study to investigate the efficacy, safety and tolerability of the monoclonal antibody ATH3G10 in patients with ST-elevation myocardial infarctioNL-OMON48214Athera Biotechnologies AB16